How does severe kidney disease affect a new Drug's levels?

NCT ID NCT06814132

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the drug MK-5684 behaves in the body of men with severe kidney disease or end-stage renal disease compared to healthy men. Twenty-four participants received a single dose, and researchers measured drug levels in the blood over time. The goal is to understand how kidney function affects the drug's processing, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-5684 (oral tablet, with prednisone and fludrocortisone acetate)
What this could lead to: If successful, this study could help doctors determine the right dose of MK-5684 for people with severe kidney problems, making treatment safer and more effective.
What could go wrong: This is a small, early-phase study focused on drug levels, not on treating disease. It may not lead to any new treatment, and results may not apply to women or people with milder kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE KIDNEY DISEASE HEALTHY PARTICIPANTS KIDNEY FAILURE, CHRONIC RENAL FAILURE , CHRONIC RENAL FAILURE, END-STAGE

Contacts and locations

Locations

Orlando Clinical Research Center ( Site 0002)

Orlando, Florida, 32809, United States
Research by Design ( Site 0001)

Chicago, Illinois, 60643, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.